The p53 gene mapped on chromosome 17p is an important negative regulator of normal cell growth and division (Finlay et al., 1989; Chen et al., 1990; Diller et al., 1990; Isaacs et at., 1991) . Alteration or inactivation of p53 by mutation can allow a cell to escape from normal into uncontrolled growth leading to cancer development. p53 mutations are a very common genetic change in a variety of human tumours Takahashi et al., 1989; Nigro et al., 1989; Bartek et al., 1990a; Marks et al., 1991; Tamura et al., 1991) . The majority of the mutations alter the conformation of the nuclear protein product, encoded by the p53 gene (Gannon et al., 1990; Bartek et al., 1990b; Rodrigues et al., 1990). In normal cells and tissues the p53 protein has a very short half-life (Oren et al., 1981 ) and attains such a low level that it is not detectable histologically (Gannon et al., 1990) . The mutant forms have an extended half-life (Finlay et al., 1988) and being overexpressed are readily detected by immunohistochemistry. Elevated p53 levels have been described in different human neoplasms (Crawford et al., 1984; Cattoretti et al., 1988; Bartek et al., 1990a; Iggo et al., 1990; Davidoff et al., 1991a; Marks et al., 1991 
Summary p53 expression was examined in 55 gastric and 107 colorectal carcinomas with an immunoperoxidase technique, using the polyclonal antibody CM1 on routinely fixed, paraffin embedded tissue. p53 protein was detected in 47% gastric and in 46% colorectal carcinomas and found to correlate with stage of disease and unfavourable clinical outcome (P<0.001). Thus, the proportion of positively reacting neoplasms increased as the stage progressed, tumours which had invaded regional lymph-nodes overexpressed p53 more frequently than localised carcinomas and an elevated level of p53 was associated with early relapse and death. In colorectal carcinoma p53 positivity was also linked with site and macroscopic configuration of the primary tumour and was most frequently expressed in carcinomas from the rectum and in ulcerative tumours. p53 overexpression was irrrespective of tumour grade. Uniform negative reactivity with anti-p53 antibody was seen in normal epithelium adjacent to carcinoma, intestinal metaplasia, atrophic gastritis and in colonic adenomas. There was a good correlation between immunohistochemical staining on paraffin and frozen sections. These studies suggest that in gastric and colorectal carcinoma, immunohistochemical detection of p53 protein in routinely fixed tissue can be used along with other established parameters to assess prognostic outcome, especially to identify patients with poor short-term prognosis.
The p53 gene mapped on chromosome 17p is an important negative regulator of normal cell growth and division (Finlay et al., 1989; Chen et al., 1990; Diller et al., 1990; Isaacs et at., 1991) . Alteration or inactivation of p53 by mutation can allow a cell to escape from normal into uncontrolled growth leading to cancer development. p53 mutations are a very common genetic change in a variety of human tumours Takahashi et al., 1989; Nigro et al., 1989; Bartek et al., 1990a; Marks et al., 1991; Tamura et al., 1991) . The majority of the mutations alter the conformation of the nuclear protein product, encoded by the p53 gene (Gannon et al., 1990; Bartek et al., 1990b; Rodrigues et al., 1990) . In normal cells and tissues the p53 protein has a very short half-life (Oren et al., 1981 ) and attains such a low level that it is not detectable histologically (Gannon et al., 1990) . The mutant forms have an extended half-life (Finlay et al., 1988) and being overexpressed are readily detected by immunohistochemistry. Elevated p53 levels have been described in different human neoplasms (Crawford et al., 1984; Cattoretti et al., 1988; Bartek et al., 1990a; Iggo et al., 1990; Davidoff et al., 1991a; Marks et al., 1991) .
However, in contrast to numerous papers on p53 overexpression in human cancer little is known about its role in determining prognosis and reports from different groups are inconsistent. Recently Scott et al. (1991) and Campo et al. (1991) (Cattoretti et al., 1988) and tumour stage (Davidoff et al., 1991a,b) .
There and for colorectal carcinoma according to the criteria of Dukes with modification by Turnbull et al. (Preece et al., 1986; Fielding & Priestman, 1986 ). There were six, 12, nine and 28 gastric cancers in stages I-IV respectively. The distribution of colorectal tumours was 13, 53, 27 and 14 in stages A-D respectively. The histopathological diagnoses and tumours localisation are shown in Tables II and III. A follow-up of patients whose tumours were examined in this study is currently in progress. The median survival of the patients operated on for gastric cancer is 21 months (range, 9-54 months) and the median survival of patients with colorectal carcinoma is 12.1 months (range 9-26 months). Only 80/107 colorectal patients' follow-up data was analysed because six died of causes unrelated to cancer, 11 (disease free) had too short a follow-up time and for ten cases the information was unavailable.
Tissue preparation
One hundred and fifty-two biopsies were obtained at surgery and ten at endoscopy (three gastric and seven colorectal carcinomas). The tissue was fixed in 10% neutral formalin and embedded in paraffin. In most of the cases, specimens from the same patients were also immediately embedded in OCT compound, frozen in liquid nitrogen and stored at -700C.
Immunohistochemistry
The polyclonal rabbit anti-p53 antibody, CM1, raised against the full length human p53 protein (purified from bacteria expressing the recombinant protein) was used for immunohistochemistry. This antibody was kindly supplied by Dr David Lane (CRC Dundee, UK). A three stage immunoperoxidase technique was used. Briefly, the slides were incubated overnight at 40C with polyclonal anti-p53 antibody, diluted 1/ 1000 for frozen and 1/750 for paraffin material. The sections were washed then treated consecutively for 30 min with biotinylated swine anti-rabbit antibody (Dakopatts, A/s Denmark) diluted 1/400 in TBS and streptavidin HRP-conjugated reagent (Dako Ltd., UK) diluted 1/800, at room temperature. Peroxidase was visualised using 0.05% solution of diaminobenzidine tetrahydrochloride (DAB, Sigma) and 0.1% solution of nickel chloride in TBS containing 0.03% hydrogen peroxide (10 min).
Finally, the slides were lightly stained in Mayer's haemalum. Replacement of the primary antibody with normal rabbit serum was used as a negative control. Colonic carcinomas sections with high p53 expression were included in each experiment to ensure that the procedure was working optimally. Only tumours which exhibited intense nuclear staining were categorised as p53 positive.
Sixty tumours (35 colorectal and 25 gastric carcinomas) were tested on paraffin and frozen material.
Statistics
The p53 expression in gastric and colorectal carcinomas was compared with prognostic clinical and histological features and with follow-up data. Statistical analysis was done with chi-square test and Fishers' Exact test, using significance level of 0.05.
Results
The results of immunohistochemical evaluation are summarised in Table I . p53 was detected in 26 out of 55 (47.3%) gastric carcinomas and in 49 out of 107 (45.8%) colorectal carcinomas. The p53 positivity rate for the colorectal carcinomas from the two centres was similar, 34/74 (45.9%) and 15/33 (45.6%) for English and Polish specimens respectively. The immunoreaction was always localised in the nucleus of neoplastic cells (Figure 1 ). The majority of p53 positive colorectal and gastric neoplasms showed a uniform immuno- The relationship between p53 expression and several clinico-pathological criteria related to prognosis is shown in Table II for gastric and Table III for colorectal carcinoma. There is a highly significant correlation between p53 expression and tumour stage in gastric and colorectal carcinoma. The proportion of positively reacting colorectal tumours increases as the stage progresses (P<0.001). This increase is also significant in gastric cancer when early stages (I and II) are compared with stages III and IV (P<0.001). Also tumours which had invaded regional lymph-nodes overexpress p53 more frequently than localised carcinomas. Only 9% (two out of 23) gastric and 30% (20 out of 66) colorectal tumours from the patients without metastases are p53 positive while 71% (20 out of 28) gastric and 63% (17 out of 27) colorectal carcinomas with positive lymph-nodes overexpress p53 protein (P <0.001 for gastric and P = 0.005 for colorectal carcinoma). p53 positivity in colorectal carcinoma correlates also with macroscopic configuration and site of the primary tumour. Ulcerative tumours are more frequently p53 positive than polypoid (P<0.001) and carcinomas from the rectum expressed p53 more often than those from the left and the right colon (P = 0.02). In gastric cancer p53 overexpression was detected most frequently in tumours from the cardia but the difference did not reach statistical significance (P = 0.27) and was irrespective of macroscopic configuration. In both gastric and colorectal carcinomas p53 expression was unrelated to tumour grade, sex and age.
A follow-up of patients whose tumours were examined in this study is currently in progress. Present results are shown in Table IV . Statistical analysis of follow-up data of 47 patients with gastric carcinoma (20 with p53 positive and 27 with p53 negative tumours) and of 80 patients operated on for colorectal cancer (36 with p53 positive and 44 with p53 negative tumours), revealed that p53 overexpression in both carcinomas is significantly associated with early relapse and death (P<0.001). Thus, 18 (Crawford et al., 1984; Remvikos et al., 1990; Rodrigues et al., 1990; Scott et al., 1991; Campo et al., 1991 (Fielding & Priestman, 1986; Preece et al., 1986) . The prognosis is worse for cancers which originate in the upper third of stomach or in the rectum. It also has been demonstrated that colorectal carcinomas of the fungating type metastasised less frequently than ulcerative tumours (Fielding & Priestman, 1986 There is no published data on the prognostic significance of p53 protein in gastric cancer and little is known about its role in determining prognosis in colorectal carcinoma. Remvikos et al. (1990) , investigated 41 colorectal tumours and found a significant association between elevated p53 and the presence of DNA aneuploidy, a factor connected with poor prognosis but not with Dukes stage. They suggested that evaluating p53 expression may prove useful in determining different biological subgroups of colorectal cancer. However, in a later study of 52 colorectal carcinomas (Scott et al., 1991) Campo et al. (1991) demonstrated that right sided tumours were less p53 immunoreactive than distal carcinomas and did not find a correlation between p53 expression and tumour differentiation. Our data are also consistent with recent studies on breast cancer which also reported a prognostic significance of p53 overexpression. Davidoff et al. (199la, b) demonstrated that frequency of p53 overexpression in breast cancer was related to stage of disease and might provide prognostic information. In a large study Cattoretti et al. (1988) also showed that p53 in mammary carcinomas was associated with oestrogen receptor-negative, growth factor receptor-positive and high grade tumours, known indicators of poor prognosis. The results reported in this paper suggest that in gastric and colorectal carcinoma alterations in p53 expression are rather late events, significantly associated with advanced stage of disease, early relapse and death. Our data also show that the polyclonal antiserum CM1 detects elevated levels of p53 protein equally well in formalin fixed, paraffin embedded or frozen material. The implication of these findings is that, immunohistochemical detection of p53 can be a valuable tool in routine pathology for p53 screening in gastric and colorectal cancer, to identify, along with other established prognostic factors, patients with poor short-term prognosis and to decide on optimal treatment for this group. We found that p53 overexpression is related to a poor prognosis, but our follow-up time does not allow conclusions on p53 negative cases. Further long-term follow-up is necessary to determine whether p53 immunostaining may delineate subsets of gastric and colorectal tumours having particular biological and clinical behaviour. Such studies are currently in progress.
